| Document |
Document Title |
|
WO/2024/003128A1 |
The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants the...
|
|
WO/2024/003493A1 |
The present invention relates to the genetic modification of bacteria in the genus Clostridium, typically solvent-producing bacteria in the genus Clostridium. The invention further relates to methods, tools and kits for deleting or modif...
|
|
WO/2024/002985A1 |
This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus a...
|
|
WO/2024/006741A1 |
The disclosure relates to compositions and methods for the preparation, use, and/or formulation of adeno-associated virus capsid protein variants.
|
|
WO/2024/003917A1 |
The present disclosure relates to modified protein having an amino acid sequence comprising at least one amino acid deletion and at least one amino acid substitution as compared to a reference protein and having improved stability.
|
|
WO/2024/003007A1 |
The present invention relates to recombinant spriviviruses, in particular a recombinant spring viraemia of carp virus, uses thereof and methods for producing the same.
|
|
WO/2024/003387A1 |
The invention relates to re-engineering of a natural microbial syringe for loading of effector proteins that are not naturally found as cargo of the specific syringe. The cargo, that is one or more effector protein and proteins required ...
|
|
WO/2024/002363A1 |
Provided herein are IL-2 mutant polypeptides and compositions thereof that exhibit reduced binding affinity to IL-2Rα and/or enhanced binding affinity to IL-2βγ. Further provided herein are methods for administering said IL-2 mutant p...
|
|
WO/2024/004869A1 |
The present invention provides a peptide that can be utilized in active targeting DDS. Provided according to an embodiment of the present invention are: a peptide that has a hydrophobic region and a hydrophilic region lower in hydrophobi...
|
|
WO/2024/003343A1 |
The present invention relates to the field of vaccination, in particular, of vaccination against hepatitis C virus (HCV). The present invention provides a composition comprising at least parts of the HCV core protein, and HCV E1 and HCV ...
|
|
WO/2024/002059A1 |
Provided is a method for treating a Parkinson's Disease, comprising a TRIM72 protein modulator. Further provided is a composition comprising the TRIM72 protein modulator and use thereof.
|
|
WO/2024/006942A1 |
The present invention provides methods for treating an inflammatory condition of the eye in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-1R ligand, or portion or variant ther...
|
|
WO/2024/005044A1 |
The present invention provides a compound represented by formula (1): [in formula (1), X is a phospholipid bilayer-penetrating peptide, Y is a hydrocarbon group that may contain oxygen, sulfur, phosphorus, or nitrogen, and Z is a polymer...
|
|
WO/2024/006940A1 |
The subject matter described herein provides methods for treating an autoimmune disease in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-1R ligand, or portion or variant there...
|
|
WO/2024/005133A1 |
Provided are: a pharmaceutical composition for treating damage to the white-white zone or red-white zone of the meniscus, said composition containing an HMGB1 fragment peptide containing an amino acid sequence delimited by SEQ ID NO 1, o...
|
|
WO/2024/003393A1 |
The invention relates to a fusion protein that comprises at least one albumin binding moiety and further comprises a tumor targeting moiety. The invention relates to the use of the fusion proteins or of compositions comprising the fusion...
|
|
WO/2024/003313A1 |
The present disclosure relates to peptide IL23 receptor antagonists, their pharmaceutical compositions and their medical use, for example in the treatment of inflammatory bowel diseases such as Crohn's disease.
|
|
WO/2024/002279A1 |
Provided are an immunocompatible human pluripotent stem cell, a method for preparing same, and use thereof. The modified human pluripotent stem cell can be induced and differentiated into various tissues/organ cells, has very ideal immun...
|
|
WO/2024/002170A1 |
Provided herein are various polypeptides comprising an IL-21 variant. Further provided herein are conjugates comprising the polypeptide and at least one additional moiety. Further provided herein are related nucleic acid molecules, vecto...
|
|
WO/2024/006931A1 |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Embodiments of derivative cells provided herein have stable and f...
|
|
WO/2024/003859A1 |
The present invention relates to a process for obtaining a composition containing a protein hydrolysate derived from collagen with high glycine content and compounds containing iodine, a composition obtained by such process, and the use ...
|
|
WO/2024/003668A1 |
The present disclosure provides methods of producing heme proteins in transgenic plants, plant tissues, or plant cells, as well as describing the expression of these heme proteins in seeds. Also, the present disclosure provides transgeni...
|
|
WO/2024/002806A1 |
Recombinant bacterial collagen-like protein with an amino acid sequence that is at least ≥ 60% identical to the amino acid sequence of SEQ ID NO:1 characterized in that the amino acid sequence comprises a deletion of at least 38 amino ...
|
|
WO/2024/005240A1 |
The present invention relates to an insulin receptor-binding aptamer dimer and uses thereof. The insulin receptor-binding aptamer dimer according to the present invention has a greater effect in activating insulin receptors compared to a...
|
|
WO/2024/006888A1 |
Aspects of the disclosure relate to genetic modifications which increase heterologous protein production in a host cell, such as a methylotrophic yeast host cell, such as Pichia pastoris. Such genetic modifications may comprise, in some ...
|
|
WO/2024/006679A1 |
This invention relates to compositions and methods for modifying an Elongated Hypocotyl5 (HY5) transcription factor in plants to suppress the shade avoidance response. The invention further relates to plants and plant parts produced usin...
|
|
WO/2024/003833A2 |
Certain aspects of the present disclosure provides systems, compositions, and methods for regulating expression or activity of a target protein in a cell. In some cases, the present disclosure provides a system comprising an actuator moi...
|
|
WO/2024/006915A2 |
Aspects of the present disclosure relate to functionalized polymers and methods of use thereof. Certain aspects are directed to polymers comprising adjuvants for use in stimulating an immune response. In some cases, provided are polymers...
|
|
WO/2024/003381A1 |
The present invention relates to hybrid polypeptides acting as dual GHSR and NPY5R agonists and their use in the treatment of cachexia or anorexia.
|
|
WO/2024/004231A1 |
The present invention addresses the problem of providing a novel γ-secretase inhibitor that has as an active ingredient a substance for which a γ-secretase inhibitory activity is heretofore unknown. The present invention provides a γ-...
|
|
WO/2024/006281A2 |
The present disclosure pertains to modified immune cells comprising chimeric switch receptors and methods of using and making immune cells comprising chimeric switch receptors. The present disclosure also pertains to modified immune cell...
|
|
WO/2024/005124A1 |
The present invention relates to: a method for producing a non-human primate model of cerebral infarction, said method including administering an endothelin to the cerebral basal ganglia and thalamic area of a non-human primate and thus ...
|
|
WO/2024/003893A1 |
The invention provides a peptide having antimicrobial activity comprising the amino acid sequence as set forth in SEQ ID No. 1 (FLNALKNFAKTAGKRLKSLLN), wherein at least one, part, or all of the amino acids of SEQ ID No. 1 are in D-config...
|
|
WO/2024/006433A1 |
Methods for production of gene-delivery vectors suitable for animal models and humans using a bacteria/mammalian dual-expression plasmid, wherein the virus-like particles may be massively produced via heterologous expression in bacteria....
|
|
WO/2024/000408A1 |
Provided are a luciferase mutant and the use thereof, and specifically provided are a copepod luciferase mutant and the use thereof. By means of performing protein directed evolution on Pxluc, a mutant which has more than 2-fold increase...
|
|
WO/2024/001242A1 |
A polypeptide and a use thereof are provided. The polypeptide comprises an N-terminal sequence and a C-terminal sequence, the N-terminal sequence comprising one or more repeating units, and said repeating unit comprising an amino acid se...
|
|
WO/2024/003416A1 |
The present invention relates to a cell line wherein the endogenous class I and/or class II HLA alleles are inactivated, the cell line further comprising (a) a polynucleotide encoding a first fluorescent marker under control of at least ...
|
|
WO/2024/003786A1 |
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting GPC3 and optionally having multiple genetic edits, including a disrupted TRAC gene, a disrupted β2M gene, a disrupted Regnase 1 gene, a disrupted TGFb...
|
|
WO/2024/002062A1 |
Provided is a TRIM72 truncated protein, comprising the Coiled-PRYSPRY domain or PRYSPRY domain or its functional fragment of a TRIM72 protein. Further provided is the use of the TRIM72 truncated protein.
|
|
WO/2024/006993A1 |
Force-sensing peptides that can be used as sensor molecules or can be used for signal transduction by detecting a force and translating the force into a biological signal are described as well as methods of using the force-sensing peptid...
|
|
WO/2024/002259A1 |
A non-human animal expressing human or chimeric (e.g. humanized) OSMR, OSM, IL31RA, and/or IL31 proteins and the use method thereof.
|
|
WO/2023/249421A1 |
The present application discloses a histidine export protein or a variant thereof having the ability to export L-histidine, which can dramatically enhance the production of L-histidine when expressed in a microorganism having the ability...
|
|
WO/2023/247427A1 |
The present invention relates to a cell line for identifying engineered common gamma chain (γc) receptors, the cell line comprising: (a) a reporter system comprising a polynucleotide encoding a fluorescent marker, wherein the polynucleo...
|
|
WO/2023/248126A1 |
A chimeric antigen receptor (CAR) that binds CD117 (anti-CD117 CAR), wherein the anti-CD117 CAR comprises: (a) an ectodomain that binds CD 117; (b) a transmembrane domain; and (c) an endodomain comprising a costimulatory domain and a CD3...
|
|
WO/2023/248212A1 |
The present invention relates to polynucleotides which, when expressed in a Triticeae plant cell, particularly wheat, barley or rye plant cells confer or enhance resistance or tolerance towards leaf rust disease and/or stripe rust diseas...
|
|
WO/2023/247468A2 |
The present invention relates to isolation and separation of kappa light chain-containing proteins. More specifically it relates to a separation matrix comprising kappa light chain-binding ligands covalently coupled to a porous support, ...
|
|
WO/2023/246570A1 |
Provided are an antibody specifically binding to IL-9, a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell comprising the nucleic acid or the vector, a pharmaceutical composition comprising the antibod...
|
|
WO/2023/245259A1 |
The present invention relates to plant growth promoting endophytes, preferably of plants of the Glycine genus, particularly plant growth promoting Curtobacterium sp. endophytes. The present invention also relates to seeds, plants, and pa...
|
|
WO/2023/247747A1 |
A non-pyrogenic Staphylococcal superantigen vaccine comprising a combination of detoxified Staphylococcal superantigen vaccine antigens which are genetically modified toxins that incorporate detoxifying mutations in its T cell receptor b...
|
|
WO/2023/250336A1 |
Provided herein, inter alia, are compositions and methods including T-cell cultures enriched for gdT cells, the gdT cells expressing a CAR, and related methods for generating said cells. In an aspect provided herein is a method for gener...
|
